Trial · NCT00149643
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
NCT00149643, Phase 2, Completed, University of Pittsburgh; results first posted 2012-09-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence. Trials, record NCT00149643. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00149643
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
- NCT number
- NCT00149643
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 70 participants, actual
- Lead sponsor
- University of Pittsburgh
- Conditions
- Depressive Disorder, Major, Cannabis Abuse
- Interventions
- Fluoxetine, Placebo
- First posted
- 2005-09-08
- Last updated
- 2013-06-24
- Results first posted
- 2012-09-03
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Days Per Week of Cannabis Use. | 12 Weeks | The number days out of the last seven days that cannabis was used. |
| Primary | Depression Symptoms at Week 12 | 12 Weeks | Average of Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10 and 12. The BDI is a subject reported measure that has a minimim score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scare (63). Each DSM-IV criteron asses a different depressive symptom. |
| Secondary | Number of Cannabis Use Disorder Criterion Met at a Particular Time Point. | 12 Weeks | Criterion used in this study was the number of DSM-IV cannabis use disorder symptoms (criteria) that were met. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Days Per Week of Cannabis Use. | 12 Weeks | Days of cannabis use per week | MEAN | |
| PRIMARY | Depression Symptoms at Week 12 | 12 Weeks | BDI Total | MEAN | |
| SECONDARY | Number of Cannabis Use Disorder Criterion Met at a Particular Time Point. | 12 Weeks | Number of DSM-IV criterion | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Days Per Week of Cannabis Use. | Fluoxetine | 3.88 | Standard Deviation 2.6 | Days of cannabis use per week | |
| Days Per Week of Cannabis Use. | Placebo | 3.1 | Standard Deviation 2.27 | Days of cannabis use per week | |
| Depression Symptoms at Week 12 | Fluoxetine | 7.79 | Standard Deviation 8.29 | BDI Total | |
| Depression Symptoms at Week 12 | Placebo | 7.31 | Standard Deviation 7.98 | BDI Total | |
| Number of Cannabis Use Disorder Criterion Met at a Particular Time Point. | Fluoxetine | 0.59 | Standard Deviation 0.79 | Number of DSM-IV criterion | |
| Number of Cannabis Use Disorder Criterion Met at a Particular Time Point. | Placebo | 0.47 | Standard Deviation 0.65 | Number of DSM-IV criterion |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Fluoxetine | 34 | |
| Overall Study | STARTED | Placebo | 36 | |
| Overall Study | COMPLETED | Fluoxetine | 0 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Fluoxetine | 34 | |
| Overall Study | NOT COMPLETED | Placebo | 36 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Fluoxetine | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Fluoxetine | 0 | 34 |
| Total, other adverse events | Placebo | 0 | 36 |
| Total, serious adverse events | Fluoxetine | 0 | 34 |
| Total, serious adverse events | Placebo | 0 | 36 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20576364 | RESULT |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA019142 | Fluoxetine for MDD/Cannabis Disorder in Young People | CORNELIUS, JACK R | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | NATIONAL INSTITUTE ON DRUG ABUSE | 2004 to 2009 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Fluoxetine vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00149643
GET https://conductscience.org/api/trials/v1/NCT00149643/registered